A federal court has ordered a Texas-based company to stop producing compounded drug products intended to be sterile until the company complies with the Federal Food, Drug, and Cosmetic Act and other requirements, the Food and Drug Administration announced today. The government alleges that Guardian Pharmacy Services distributed purportedly sterile drug products made under unsanitary conditions and in violation of current good manufacturing practice requirements. According to the complaint, the company also made and distributed misbranded drugs because their labels did not include adequate directions for patient use, were false or misleading. In 2017, the FDA received adverse event reports concerning at least 43 patients who received eye injections during cataract surgery of a drug compounded by Guardian.

Related News Articles

Headline
The Joint Commission June 30 announced a new, streamlined process that removes 714 requirements from its hospital accreditation program. The new program,…
Headline
AHA President and CEO Rick Pollack explains how hospitals have made meaningful progress in patient safety and delivering high-quality care, in a column…
Headline
A 60-day appeal window has passed for the Food and Drug Administration to appeal a federal court ruling that invalidated its final rule to regulate laboratory-…
Headline
The AHA May 12 responded to the Office of Management and Budget's April 11 request for information on regulatory relief, making 100 suggestions to the Trump…
Headline
The AHA Living Learning Network is launching the Quality Exchange, a virtual collaborative for health care quality and patient safety professionals at…
Headline
The U.S. District Court for the Eastern District of Texas March 31 ruled that the Food and Drug Administration does not have the authority to regulate…